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On September 14
th, 2009, the presi-
dents of five United States universities—
Boston University, Brown, Duke, Johns
Hopkins, and the University of Washing-
ton—and representatives of over 50 North
American institutions convened for the
first meeting of the Consortium of Uni-
versities for Global Health (http://www.
cugh.org). The meeting was in response to
the demonstrated passion and interest of
students in the field of global health and
the responses needed from universities to
cope with increasing student interest in
this field. Of 37 institutions surveyed that
feature global heath programs, the num-
ber of undergraduate and master’s level
students studying in the field has doubled
since 2006. In this arena, growing student
movements have helped lead the way.
Organizations such as Clinton Global
Initiative Universities have also successful-
ly tapped into university student interest in
global public health outreach and re-
search. To be sure, universities are well
poised to lead such a movement for global
health: They are independent organiza-
tions, boast central missions to promote
public welfare, and possess copious re-
sources and knowledge to share with
partner institutions globally [1].
All the while, what remains overlooked
in this rapidly expanding global health
movement is real innovation for preven-
tion and treatment of the diseases of
poverty; existing drugs, some more than
50 years old, accrue microbial resistance
and, on the whole, exist only in unadjusted
dosages for pediatric patients [2]. What’s
more, some drugs (e.g., the arsenicals and
pentamadine) exhibit toxicities that we
would consider unacceptable if they were
widely used in the developed world.
The innovation gap for the diseases
of poverty is growing at a frightening
pace. For instance, some estimates indicate
that the total research and development
funding for diabetes is more than 15 times
that of malaria, and more than 100 times
that of other parasitic infections such as
hookworm, elephantiasis, and schistosomi-
asis. Because these diseases almost exclu-
sively afflict the world’s poorest people we
must look to universities to provide some of
the leadership on this issue. Other funding
bodies—including the US National Insti-
tutes of Health (NIH)—are providing fresh
capital for basic science research, but more
funds are needed to cope with the global
burden of neglected diseases [3]. Certainly,
Dr. Francis Collins, the new NIH Director,
has affirmeda strongcommitment to global
health in his strategic vision. but while we
feel that he has made almost heroic efforts
to ensure prioritization of a global health
research agenda, the harsh reality is that
the NIH budget has been essentially flat
since 2003 [4]. The American Recovery
and Reinvestment Act committed to $10
billion of stimulus funds to the NIH,
US$8.2 billion of which is to be directed
to scientific research priorities [5].
Treating the full range of diseases
prominent in the global health arena is
important. While we advocate an increase
in the overall investment in global health
disease research, we specifically call for a
new and prominent focus on research for
neglected tropical diseases (NTDs), a
group of infections that together rival the
disease burdens of more widely known
global health epidemics, yet receive espe-
cially limited research and development
[6]. The most recent global estimate of
funding on all neglected diseases is at
US$3 billion, with nearly three-quarters of
the research funds earmarked for HIV/
AIDS (40%), tuberculosis (15%), and
malaria (18%) [7]. Just 0.4% of this pot
(less than $10 million each) is targeted for
diseases like leprosy, Buruli ulcer, or
trachoma which affects over a billion
people, 16% of the global population [7].
By increasing funding not only
for global health research, but
also for research in NTDs,
universities could make an
impact twice as strong
Right now, there are approximately 50
U.S. universities with endowments that
exceed US$1 billion, and yet their contri-
bution to global health research, imple-
mentation, and training remains relatively
meager. For the most part, research and
education for the neglected diseases in
developing countries are still not a substan-
tial component of most university agendas.
At most of our nation’s major research
universities, internal budgets devoted to
global health research are far below the
annual salaries of their university presidents
and chief executive officers. Despite stated
public commitments to global health, many
of the university centers with global health
armsarestill supported with external funds.
So how can research universities further
harness student and faculty interest in
global health to make a meaningful impact
for NTD research?
Here, we propose three specific steps.
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develop new seed funds for
NTD research
Similar to the call by the United
Nations for countries to donate 0.7% of
their GDP to help reach the Millennium
Development Goals, this would represent
a concrete university commitment to
neglected disease research, training, and
education. The dollar amount of the fund
could vary by school, but a useful rubric
could be the salary of the university
president (for example). The median
salary of a private university president is
US$627,750, with 23 presidents making
more than $1 million [8,9].
What would these funds accomplish?
They would not be enough to seed new
laboratories but could supplement existing
ones, such as for new graduate student
fellowships or fresh interdisciplinary sym-
posia (e.g., in evolutionary microbiology).
As an example, the University of Pennsyl-
vania has gone so far as to create
interdisciplinary professorships in global
health, called ‘‘Integrating Knowledge
Professors,’’ with similar funds [5]. The
bulk of these funds could be used to fund
innovative new US$100,000 projects in
the spirit of the Gates Explorations.
Alternatively, these funds could provide
operational support for neglected diseases
centers, like the existing center at the
University of California. Berkeley, or
finance core facilities that develop and
maintain novel transgenic parasite lines.
The start-up funds could also be used to
help recruit human resources and labora-
tory space for product development part-
nerships. The funds may even help
provide fellowship support between uni-
versities internationally (e.g., Duke and the
National University of Singapore’s part-
nership in dengue research). This collab-
orative effort may be key in empowering
countries to sustainably address their own
health epidemics while building capacity
for scientific research. Funding could also
go toward a subsidy or partial fee waiver
for students in certain global health
programs who partake in a social service
related to neglected diseases—akin to the
Global Science Corps (Princeton Univer-
sity; http://sites.ias.edu/sig/gsc). The pos-
sibilities are limitless, but with a university
seed fund for diseases of poverty a little
would go a long way.
Second, universities should
eliminate barriers concerning
intellectual property around
neglected diseases
It’s no secret that current intellectual
property schemes hinder both innovation
and access to essential medicines for the
poor in developing countries [10]. To
ensure that licensed innovations remain
available for drug development, universi-
ties should create a research exemption for
neglected diseases, retaining all intellectual
property rights for the purpose of neglect-
ed disease research.
On November 9
th, 2009, six universi-
ties—Harvard, Yale, Boston University,
Oregon Health Sciences University, the
University of Pennsylvania, and Brown)—
along with the Association of University
Technology Managers announced a plan
to facilitate access to university innova-
tions with a clause ensuring global access
to low-cost products by manufacturers for
treatment of infectious diseases [11,12].
The NIH and the US Centers for Disease
Control have also signed on, but many
other universities and institutes have not.
Already, several health products (e.g.,
drugs, vaccines, and diagnostics) for ne-
glected diseases are being developed at
University of North Carolina Chapel Hill
(African sleeping sickness), University of
California (Chagas disease, malaria, and
schistosomiasis), Sabin Vaccine Institute-
George Washington University (hook-
worm and schistosomiasis), and Washing-
ton University St. Louis (lymphatic filari-
asis), but care should be taken to ensure
that needless intellectual property barriers
do not stand in the way of developing new
life-saving tools.
The University of British Columbia’s
new collaboration with iCo Therapeutics
to develop and distribute a new low-cost
oral formulation of Amphotericin B for
visceral leishmaniasis underscores the po-
tential for leadership by universities to
push forward alternative (non-financial)
metrics for exercising technology transfer
[13]. Even baby steps forward—such as
providing extra support for talented uni-
versity technology transfer officers to help
develop new therapies for neglected dis-
eases—have immeasurable symbolic and
material benefits.
Third, new metrics for faculty
appointments that value
neglected disease research
should be implemented
The lack of funding, but also the lackof a
proper home (professional organizations
that provide financial and professional
support for academic advancement), for
interdisciplinary research is a real issue.
Some deans and department chairs show a
lack of interest in global health [5] or
neglected disease research programs, often
in sharp contrast to the interest of their
students, trainees, and faculty. The simple
rubric of high-impact publications au-
thored and grants received needs to be re-
evaluated for this field. The scientific
hurdles in the fields of parasitology, for
example, where expression systems, muta-
genesis, or knockouts can take months (if
not years) need to be balanced with
comparison to the work of researchers
using other model systems. Alternative
metrics might, for instance, reward work
based on how many quality- and disability-
adjusted life years (QALYs and DALYs)are
saved [14].
Put frankly, from the perspective of the
two graduate student authors (SPK, GT),
the current incentives for entering and
staying in neglected disease research are
few and far between. And what’s worse is
the danger of our universities (and their
researchers) choosing research problems
based on their potential commercial value.
Devising and developing therapies for the
diseases of poverty is not profitable, but
the dividends of developing life-saving
therapies are priceless. If our universities
won’t deliver, who will?
University constituents can be prime
movers in this field. These commitments
will be strengthened only by formal uni-
versity commitment from the highest levels
andunprecedenteduniversitycollaboration
designed to prioritize global public health.
At the turn of the 20
th century, the
presidents of our most prominent universi-
ties led the way in reforming medical
education in the US and creating the
beginnings of today’s medical research
juggernaut in the developed world. Now,
they stand at the cusp of promoting health
around the world. Though this is exciting,
we question whether real in-house univer-
sity commitments will now match the
fanfare. Will universities put their money
where their mouths are?
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